Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, Ltd., an Israeli biotechnology company, says that in HIV infected people a switch in concentration of Th1 and Th2 helper cells occurs. This causes suppression of a person's natural cellular immunity. Dr. Michael Har-Noy indicates that this helper cell switch is also correlated with the development of full-blown AIDS. Correcting this Th1-Th2 imbalance in HIV infected patients might improve cellular immune function and prevent opportunistic infection. Multiple intradermal
AlloStimTM injections in cancer patients have induced a favorable Th2-Th1 reversal. This phenomenon may be of great benefit to HIV infected patients.
In HIV infected patients, CD4+ cells are targeted by the HIV virus, causing low CD4+ counts and a lack of helper cell function. Dr. Michael Har-Noy indicates that in HIV infected patients, remaining CD4+ helper cells are mostly of Th2 or Th0 variety, thereby resulting in poor cellular immunity. Multiple intradermal AlloStimTM injections have been shown to increase circulating CD4+ Th1 memory cell titers. Dr. Michael Har-Noy goes on to say that bolstering the CD4+ Th1 cell titer can restore helper function, as the HIV virus replicates primarily in Th2 cells. Increasing the CD4+ Th1 memory cell count may be of great benefit, as these cells can resist HIV infection.
Dr. Michael Har-Noy says that interleukin 12 (IL-12) is significantly suppressed in patients with the HIV virus. IL-12, produced by mature dendritic cells and macrophages, is an important cytokine which promotes Th1 cellular immunity. Intravenous infusion of AlloStimTM after intradermal priming raises serum IL-12 levels for months after administration. Dendritic cells and macrophages that mature in the presence of IL-12 are resistant to infection by the HIV virus. Therefore, says Dr. Michael Har-Noy, restoration of IL-12 production by these mature dendritic cells should strengthen Th1 cellular immunity in HIV-infected patients.
Dr. Michael Har-Noy is currently conducting a Phase I/II pilot study of AlloStimTM administration in HIV-infected patients. For more information, visit www.immunocare.net